Director/PDMR Shareholding

RNS Number : 6409H
GlaxoSmithKline PLC
24 February 2010
 



Notification of Transactions of Directors and Persons Discharging Managerial Responsibility

 

 

Vesting of 2007 GlaxoSmithKline Performance Share Plan Awards

 

The three-year performance period for the GlaxoSmithKline Performance Share Plan (the Performance Share Plan) awards made in 2007, which commenced on 1 January 2007, came to an end on 31 December 2009.

 

The Remuneration Committee considered the performance achieved in respect of the PSP awards and determined that the:

 

·     awards granted to Executive Directors and CET members in office in 2007 were dependent on Total Shareholder Return (TSR) performance. The Company ranked at the median of the comparator group and therefore 35% of the awards subject to the TSR measure vested.

 

·     awards granted in 2007 to senior executives who have since been appointed a CET member, were dependent in part on TSR performance and in part on EPS performance. Half of these awards lapsed as GSK's EPS performance conditions were not met, and 35% of the half of the awards subject to the TSR performance measure vested.

 

The following Performance Share Plan awards made to the Executive Directors and CET members in office in 2007, vested in part on 23 February 2010 and the balance of the award lapsed, as set out in the table below:

 


Awards vesting under TSR measure - 35% of award

 

Ordinary Shares

ADSs

Mr A Witty*

29,750


Mr J S Heslop*

36,750


Mr M Slaoui*


24,150

Mr J M Clarke

26,950


Mr M Dunoyer

10,150


Mr D Learmouth

7,438


Mr W C Louv


8,750

Mr D J Phelan


13,475

Mr D Pulman


8,750

* denotes an Executive Director

 

Half of the award made in 2007 to senior executives who have since been appointed a CET member lapsed, the other half of the award vested in part (35%), the balance lapsed, on 23 February 2010 as set out in the table below:  

 


Awards that have not vested under EPS measure

 

Awards vesting under TSR measure - 35% of TSR portion of award

 

Ordinary Shares

Ordinary Shares

Mr S M Bicknell

4,440

1,554

Mr E J Gray

5,900

2,065

Mr D S Redfern

5,900

2,065

Mr J R Stephenne

13,300

4,655

Ms C Thomas

4,440

1,554

 

The Company and PDMRs were advised of these transactions on 24 February 2010.

 

This notification is made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

 

V Whyte

Deputy Company Secretary

 

24 February 2010

 

Enquiries:



UK Media enquiries:

Philip Thomson

(020) 8047 5502


Claire Brough

(020) 8047 5502


Stephen Rea

(020) 8047 5502


Alexandra Harrison

(020) 8047 5502







US Media enquiries:

Nancy Pekarek

(919) 483 2839


Mary Anne Rhyne

(919) 483 2839


Kevin Colgan

(919) 483 2839


Sarah Alspach

(919) 483 2839




European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564


Sally Ferguson

(020) 8047 5543


Gary Davies

(020) 8047 5503




US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419


Jen Hill Baxter

(215) 751 7002

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSVZLFLBLFBBBD

Companies

GSK (GSK)
UK 100

Latest directors dealings